{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T13:40:51Z","timestamp":1693143651910},"reference-count":50,"publisher":"Japanese Society of Internal Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,5,15]]},"DOI":"10.2169\/internalmedicine.4768-20","type":"journal-article","created":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T22:09:12Z","timestamp":1605478152000},"page":"1533-1539","source":"Crossref","is-referenced-by-count":4,"title":["Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy"],"prefix":"10.2169","volume":"60","author":[{"given":"Kaname","family":"Miyashita","sequence":"first","affiliation":[{"name":"Department of Haematology, Saiseikai Fukuoka General Hospital, Japan"},{"name":"Department of Hematology, National Hospital Organization Kyushu Cancer Center, Japan"},{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yui","family":"Hongo","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Saiseikai Fukuoka General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Division of Pathology, Saiseikai Fukuoka General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiya","family":"Kato","sequence":"additional","affiliation":[{"name":"Division of Pathology, Saiseikai Fukuoka General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Kusano","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shusuke","family":"Morizono","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan"},{"name":"Department of Hepatology, Saiseikai Fukuoka General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Higashi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan"},{"name":"Department of Hepatology, Saiseikai Fukuoka General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Fakih MG. Metastatic colorectal cancer: current state and future directions. J Clin Oncol 33: 1809-1824, 2015.","DOI":"10.1200\/JCO.2014.59.7633"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Johnson DH, Schiller JH, Bunn PA Jr. Recent clinical advances in lung cancer management. J Clin Oncol 32: 973-982, 2014.","DOI":"10.1200\/JCO.2013.53.1228"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Harbeck N, Gnant M. Breast cancer. Lancet 389: 1134-1150, 2017.","DOI":"10.1016\/S0140-6736(16)31891-8"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 366: 2008-2016, 2012.","DOI":"10.1056\/NEJMct1114348"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Thatishetty AV, Agresti N, O&apos;Brien CB. Chemotherapy-induced hepatotoxicity. Clin Liver Dis 17: 671-686, ix-x, 2013.","DOI":"10.1016\/j.cld.2013.07.010"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Bahirwani R, Reddy KR. Drug-induced liver injury due to cancer chemotherapeutic agents. Semin Liver Dis 34: 162-171, 2014.","DOI":"10.1055\/s-0034-1375957"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Arcaini L, Merli M, Passamonti F, et al. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin&apos;s lymphomas. Am J Hematol 85: 46-50, 2010.","DOI":"10.1002\/ajh.21564"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 3: 333-340, 2002.","DOI":"10.1016\/S1470-2045(02)00773-8"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 11: 209-219, 2014.","DOI":"10.1038\/nrgastro.2013.216"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 9: 156-166, 2012.","DOI":"10.1038\/nrclinonc.2012.1"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Castillo I, Pardo M, Bartolome J, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 189: 7-14, 2004.","DOI":"10.1086\/380202"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Pham TNQ, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 78: 5867-5874, 2004.","DOI":"10.1128\/JVI.78.11.5867-5874.2004"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Pham TNQ, Coffin CS, Michalak TI. Occult hepatitis C virus infection: what does it mean? Liver Int 30: 502-511, 2010.","DOI":"10.1111\/j.1478-3231.2009.02193.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Carreno V. Seronegative occult hepatitis C virus infection: clinical implications. J Clin Virol 61: 315-320, 2014.","DOI":"10.1016\/j.jcv.2014.09.007"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Carreno V, Pardo M, Lopez-Alcorocho JM, Rodriguez-Inigo E, Bartolome J, Castillo I. Detection of hepatitis C virus (HCV) RNA in the liver of healthy, anti-HCV antibody-positive, serum HCV RNA-negative patients with normal alanine aminotransferase levels. J Infect Dis 194: 53-60, 2006.","DOI":"10.1086\/504692"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Bartolome J, Lopez-Alcorocho JM, Castillo I, et al. Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C. J Virol 81: 7710-7715, 2007.","DOI":"10.1128\/JVI.02750-06"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin&apos;s lymphoma: systematic review and meta-analysis. Gastroenterology 125: 1723-1732, 2003.","DOI":"10.1053\/j.gastro.2003.09.025"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Coppola N, Pisaturo M, Guastafierro S, et al. Absence of occult hepatitis C virus infection in patients under immunosupressive therapy for oncohematological diseases. Hepatology 54: 1487-1489, 2011.","DOI":"10.1002\/hep.24436"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Farahani M, Bokharaei-Salim F, Ghane M, Basi A, Meysami P, Keyvani H. Prevalence of occult hepatitis C virus infection in Iranian patients with lymphoproliferative disorders. J Med Virol 85: 235-240, 2013.","DOI":"10.1002\/jmv.23460"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kisiel E, Radkowski M, Pawelczyk A, et al. Seronegative hepatitis C virus infection in patients with lymphoproliferative disorders. J Viral Hepat 21: 424-429, 2014.","DOI":"10.1111\/jvh.12181"},{"key":"21","unstructured":"21. Helaly GF, Elsheredy AG, El Basset Mousa AA, Ahmed HK, Oluyemi AE. Seronegative and occult hepatitis C virus infections in patients with hematological disorders. Arch Virol. Forthcoming."},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106: 3725-3732, 2005.","DOI":"10.1182\/blood-2005-01-0016"},{"key":"23","first-page":"518","volume":"38","author":"CT Wai","year":"2003","unstructured":"23. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38: 518-526, 2003.","journal-title":"Hepatology","ISSN":"http:\/\/id.crossref.org\/issn\/0270-9139","issn-type":"print"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43: 1317-1325, 2006.","DOI":"10.1002\/hep.21178"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet 372: 321-332, 2008.","DOI":"10.1016\/S0140-6736(08)61116-2"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Radkowski M, Gallegos-Orozco JF, Jablonska J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 41: 106-114, 2005.","DOI":"10.1002\/hep.20518"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Lefrere JJ, Guiramand S, Lefrere F, et al. Full or partial seroreversion in patients infected by hepatitis C virus. J Infect Dis 175: 316-322, 1997.","DOI":"10.1093\/infdis\/175.2.316"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6: 578-582, 2000.","DOI":"10.1038\/75063"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Kondili LA, Chionne P, Costantino A, et al. Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population. Gut 50: 693-696, 2002.","DOI":"10.1136\/gut.50.5.693"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 36: S65-S73, 2002.","DOI":"10.1053\/jhep.2002.36815"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 362: 2095-2100, 2003.","DOI":"10.1016\/S0140-6736(03)15109-4"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Hadlich E, Alvares-Da-Silva MR, Dal Molin RK, Zenker R, Goldani LZ. Hepatitis C virus (HCV) viremia in HIV-infected patients without HCV antibodies detectable by third-generation enzyme immunoassay. J Gastroenterol Hepatol 22: 1506-1509, 2007.","DOI":"10.1111\/j.1440-1746.2006.04614.x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Netski DM, Mosbruger T, Astemborski J, Mehta SH, Thomas DL, Cox AL. CD4+ T cell-dependent reduction in hepatitis C virus-specific humoral immune responses after HIV infection. J Infect Dis 195: 857-863, 2007.","DOI":"10.1086\/511826"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Kalantar-Zadeh K, Miller LG, Daar ES. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis 46: 290-300, 2005.","DOI":"10.1053\/j.ajkd.2005.05.006"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Barril G, Castillo I, Arenas MD, et al. Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol 19: 2288-2292, 2008.","DOI":"10.1681\/ASN.2008030293"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Bokharaei-Salim F, Keyvani H, Monavari SH, et al. Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease. J Med Virol 83: 989-995, 2011.","DOI":"10.1002\/jmv.22044"},{"key":"37","unstructured":"37. Gatserelia L, Sharvadze L, Karchava M, Dolmazashvili E, Tsertsvadze T. Occurrence of occult HCV infection among Hiv infected patients in Georgia. Georgian Med News 226: 37-41, 2014."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. De Marco L, Gillio-Tos A, Fiano V, et al. Occult HCV infection: an unexpected finding in a population unselected for hepatic disease. PLoS One 4: e8128, 2009.","DOI":"10.1371\/journal.pone.0008128"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. De Marco L, Manzini P, Trevisan M, et al. Prevalence and follow-up of occult HCV infection in an Italian population free of clinically detectable infectious liver disease. PLoS One 7: e43541, 2012.","DOI":"10.1371\/journal.pone.0043541"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Lin H, Chen X, Zhu S, et al. Prevalence of occult hepatitis C virus infection among blood donors in Jiangsu, China. Intervirology 59: 204-210, 2016.","DOI":"10.1159\/000455854"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Naghdi R, Ranjbar M, Bokharaei-Salim F, et al. Occult hepatitis C infection among hemodialysis patients: a prevalence study. Ann Hepatol 16: 510-513, 2017.","DOI":"10.5604\/01.3001.0010.0277"},{"key":"42","doi-asserted-by":"publisher","unstructured":"42. Torres HA, Hosry J, Mahale P, Economides MP, Jiang Y, Lok AS. Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study. Hepatology 67: 36-47, 2018.","DOI":"10.1002\/hep.29344"},{"key":"43","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1182\/blood-2006-08-041525","volume":"109","author":"G Lake-Bakaar","year":"2007","unstructured":"43. Lake-Bakaar G, Dustin L, McKeating J, Newton K, Freeman V, Frost SD. Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood 109: 845-846, 2007.","journal-title":"Blood","ISSN":"http:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"44","doi-asserted-by":"publisher","unstructured":"44. Ennishi D, Maeda Y, Niitsu N, et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 116: 5119-5125, 2010.","DOI":"10.1182\/blood-2010-06-289231"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Ennishi D, Terui Y, Yokoyama M, et al. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am J Hematol 83: 59-62, 2008.","DOI":"10.1002\/ajh.21022"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Kawatani T, Suou T, Tajima F, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 67: 45-50, 2001.","DOI":"10.1034\/j.1600-0609.2001.067001045.x"},{"key":"47","doi-asserted-by":"publisher","unstructured":"47. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 78: 2210-2215, 1996.","DOI":"10.1002\/(SICI)1097-0142(19961115)78:10<2210::AID-CNCR24>3.0.CO;2-0"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Locasciulli A, Bruno B, Alessandrino EP, et al. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)\/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant 31: 295-300, 2003.","DOI":"10.1038\/sj.bmt.1703826"},{"key":"49","doi-asserted-by":"publisher","unstructured":"49. Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 347: 92-93, 1996.","DOI":"10.1016\/S0140-6736(96)90212-3"},{"key":"50","doi-asserted-by":"publisher","unstructured":"50. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43: 209-220, 2006.","DOI":"10.1002\/hep.21051"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/10\/60_4768-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T04:01:23Z","timestamp":1621051283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/10\/60_4768-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,15]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4768-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,15]]}}}